Repairing the Defect of Intervertebral Disc With Autologous BMSC and Gelatin Sponge After Microendoscopic Discectomy for Lumbar Disc Herniation

Lumbar Disc Herniation Clinical Trial

Official title:

A Prospective, Comparative Study to Evaluate Effectiveness of Repairing the Defect of Intervertebral Disc With Autologous BMSC and Gelatin Sponge After Microendoscopic Discectomy for Lumbar Disc Herniation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03002207
• Other study ID #: 2016(001)
• Status: Recruiting
• Phase: N/A
• Start date: October 2016
• Est. completion date: December 2022

Study information

• Verified date: October 2021
• Source: Tianjin Hospital
• Contact: Baoshan Xu
• Phone: 86-13502028198
• Email: xubaoshan99[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this prospective study the investigators seek to evaluate clinical outcomes after repairing the defect of intervertebral disc with autologous BMSC/gelatin sponge during microendoscopic discectomy for participants of lumbar disc herniation.

Description:

The participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and they are divided into four groups depend on whether the defect is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge or not and whether the defect is sutured or not. In the first group,the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge and sutured. In the second group, the defect of intervertebral disc is repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge but not sutured after discectomy. In the third group, the defect of intervertebral disc is sutured but not repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy. In the four group, the defect of intervertebral disc is neither sutured nor repaired with autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 2022
• Est. primary completion date: November 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Participants with signs and symptoms of lumbar disc herniation requiring surgical treatment after conservative management;

2. Radiological data on CT/MRI obtained within a period prior to enrollment;

3. Participants give written informed consent before enrollment.

Exclusion Criteria:

1. If participants had an incomplete medical record;

2. Participants had spine tumor, spine infection, previous underwent lumbar surgery, or revision surgery.

3. Participants are taking uninterruptible anticoagulation therapy.

4. Dementia and/or inability to give informed consent.

5. MRI contraindication (e.g. cerebral aneurysm clips, cochlear implants, pacemaker, implanted biostimulators);

6. Pregnancy;

7. Participation in other clinical trial within the last 30 days.

Related Conditions & MeSH terms

• Hernia
• Lumbar Disc Herniation

Intervention

Device:
• Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge
Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.

Procedure:
• The defect is sutured
Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect is sutured after discectomy.

Locations

Country	Name	City	State
China	Tianjin Hospital	Tianjin

Sponsors (1)

Lead Sponsor	Collaborator
Zhanghao

Country where clinical trial is conducted

China, 

References & Publications (3)

Hernigou P, Poignard A, Beaujean F, Rouard H. Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J Bone Joint Surg Am. 2005 Jul;87(7):1430-7. — View Citation

Pettine KA, Murphy MB, Suzuki RK, Sand TT. Percutaneous injection of autologous bone marrow concentrate cells significantly reduces lumbar discogenic pain through 12 months. Stem Cells. 2015 Jan;33(1):146-56. doi: 10.1002/stem.1845. — View Citation

Sakai D, Andersson GB. Stem cell therapy for intervertebral disc regeneration: obstacles and solutions. Nat Rev Rheumatol. 2015 Apr;11(4):243-56. doi: 10.1038/nrrheum.2015.13. Epub 2015 Feb 24. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The Medical Records	The Medical Records including operative time?blood loss and hospital stay	1 months after hospital discharge
Primary	Changes from baseline in Oswestry Disability Index(ODI)	The self-completed questionnaire contains ten topics concerning intensity of pain, lifting, ability to care for oneself, ability to walk, ability to sit, sexual function, ability to stand, social life, sleep quality, and ability to travel.Each topic category is followed by 6 statements describing different potential scenarios in the patient's life relating to the topic. The patient then checks the statement which most closely resembles their situation. Each question is scored on a scale of 0-5 with the first statement being zero and indicating the least amount of disability and the last statement is scored 5 indicating most severe disability. The scores for all questions answered are summed, then multiplied by two to obtain the index (range 0 to 100). Zero is equated with no disability and 100 is the maximum disability possible.	Baseline, post-op 3 months, 6 months,12 months
Secondary	Changes from baseline in Visual Analogue Scale(VAS)	Self reported pain using a 10-point visual analogue scale (0=no pain;10=pain as bad as can be)	Baseline, post-op 3 months, 6 months,12 months
Secondary	Changes from baseline in The Short Form (36) Health Survey(SF-36)	The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.	Baseline, post-op 3 months, 6 months,12 months
Secondary	Change from Baseline in Magnetic Resonance Classification of Lumbar Intervertebral Disc Degeneration(Pfirrmann classification)	The Pfirrmann grading system assesses degenerated intervertebral discs by MRI for the asymmetry in disc structure, distinction of the nucleus and the annulus, signal intensity of intervertebral discs and height of intervertebral discs and assigns grade I to V for disc degeneration?	Baseline, post-op 12 months
Secondary	Change from Baseline in The Height of Disc on MRI Scans	Using imaging software, physicians will measure disc height at the treatment discs on the midline T1 sagittal view	Baseline, post-op 12 months
Secondary	Change from Baseline in The Size of Disc Protrusion	We will measure the anteroposterior (AP) size of the disc protrusions that required treatment	Baseline, post-op 12 months